Preservative free insulin formulations and systems and methods for aerosolizing
One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation includes a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation.
1. A method for aerosolizing an insulin formulation, the method comprising:
providing a preservative free insulin formulation comprising a major amount of water, and minor amounts of insulin, HCl and NaOH;
supplying an amount of the insulin formulation in the range from about 40 μL to about 200 μL to a rear side of an aperture plate having a plurality of apertures where the amount is stored while resting on the rear side by force of gravity, wherein the aperture plate is dome shaped in geometry, and wherein the aperture plate is vibrated by an annular piezoelectric element that circumscribes the apertures;
vibrating the aperture plate with the annular piezoelectric element while the amount of the insulin formulation is at the rear side, wherein vibration causes the supplied insulin to be ejected from a front side of the aperture plate that is beneath the rear side as an aerosolized spray without substantial foaming of the insulin formulation.
2. A method as in claim 1 , wherein at least about 97% of the formulation is ejected.
3. A method as in claim 2 , wherein the amount of the insulin formulation has a volume of up to about 100 microliters, and wherein the time to aerosolize to at least about 97% is less than about 11 seconds.
4. A method as in claim 1 , further comprising vibrating the aperture plate with an amplitude that is less than about 2 μm.
5. A method as in claim 1 , wherein the aerosolized spray comprises aerosolized droplets having a mean size in the range from about 3 μm to about 8 μm.
6. A method as in claim 1 , wherein the formulation has less than about 3% converted to foam when vibrating the aperture plate.
7. A method as in claim 1 , wherein the insulin has a concentration of about 100 IU/ml to about 1200 IU/ml of human insulin.
8. A method as in claim 1 , wherein the aperture plate has apertures having a size in the range from about 3 μm to 8 μm, and is vibrated at a frequency in the range from about 50 kHz to about 150 kHz.
9. A method as in claim 1 , wherein the insulin formulation further comprises 2 to 4 Zn 2+ per insulin hexamer.
10. An aerosolization system, comprising:
an inhaler comprising a housing defining a mouthpiece, an aerosol generator disposed in the housing, wherein the aerosol generator comprises a vibratable membrane having a front face, a rear face and a plurality of apertures, wherein the rear face is vertically above the front face and is exposed to the atmosphere and a vibratable element used to vibrate the membrane, wherein the membrane is dome shaped in geometry, and wherein the vibratable element is annular in geometry and circumscribes the apertures;
a container containing a volume of an insulin formulation comprising a major amount of water, a minor amount of insulin, a minor amount of HCl, and a minor amount of NaOH, wherein the formulation is preservative free such that the formulation may be aerosolized using a vibrating aperture plate without substantial foaming of the formulation, and wherein the container is positioned vertically above the rear face such that the volume of insulin is gravity fed to the rear face where it is held by gravity until it is aerosolized solely by vibration of the aperture plate, wherein the container is configured to dispense a metered amount of insulin formulation, and wherein the metered amount of insulin formulation is in the range from about 40 μL to about 200 μL, wherein the diameter of the membrane is about 5 mm to about 8 mm such that the metered amount may be held on the rear face until aerosolized.
11. A system as in claim 10 , wherein the insulin has a concentration of about 100 IU/ml to about 1200 IU/ml of human insulin.
12. A system as in claim 11 , wherein the aperture plate has apertures having a size in the range from about 3 μm to 8 μm.
13. A system as in claim 11 , wherein the vibratable membrane is configured to vibrate with an amplitude that is less than about 2 μm.
14. A system as in claim 10 , wherein the insulin formulation further comprises 2 to 4 Zn 2+ per insulin hexamer.